Hydroxychloroquine, chloroquine and other potential COVID-19 treatments
During two of this week’s White House briefings, President Trump referred specifically to two potential treatments that have been identified by medical researchers and clinicians, and that have undergone various degrees of investigation and testing in the ongoing fight against the global coronavirus pandemic. It’s important to note upfront that regardless of what you may have heard, from Trump or any other sources, no drugs or treatments have been proven as effective for either the prevention of contracting COVID-19 or for its treatment.
That said, a number of different clinical studies are currently in progress all over the world, and in the U.S., the National Institutes of Health is looking to fill a 400-volunteer study that will provide clinical results related to use of redeliver, an antiviral drug developed by Gilead originally as a treatment for Ebola, but it’s still only in clinical trials even for treatment of that disease. This study could also add other drug candidates as additional test therapies. Meanwhile, studies in China and France have examined the effectiveness of anti-malarial drugs, including chloroquine and hydroxychloroquine — including one small-scale study that suggests the positive effects of hydroxychloroquine in reducing both the duration and symptoms of COVID-19 in combination with an antibiotic called azithromycin.
The important thing to keep in mind when considering these or any other potential treatments for the novel coronavirus, which is still relatively young, is that a lot of what we know about them so far is effectively anecdotal, and not based on the kind of scientifically rigorous controlled clinical studies that are normally used in the years-long development and certification of drugs. Instead, treatments like redeliver and chloroquine/hydroxychloroquine are being deployed in the field by healthcare practitioners based on their approved use in similar (but crucially not the same) situations, like the Ebola and SARS outbreaks.
Often, they’re being used under what’s called “compassionate” grounds in the U.S. This effectively amounts to employing a drug that’s not yet certified for general use in treatment of a patient whose condition is so severe that a doctor is willing to go to desperate lengths to try to alleviate their symptoms. This has the advantage of sidestepping typical testing and approval procedures and requiring that the results of its use are documented, which contributes to the overall body of clinical knowledge in terms of its effects and interactions with patients and with COVID-19.
It’s not a clinical study, however, and that means there are still a lot of unknowns when it comes to its use that just can’t be learned or asserted based on scattered, individual instances of compassionate care treatment.
“As the Commissioner of FDA and the president mentioned yesterday, we’re trying to strike a balance between making something with the potential of an effect available to the American people, at the same time that we do it under the auspices of a protocol that would give us information to determine if it’s truly safe and truly effective,” explained National Institute of Allergy and Infectious Diseases Director Dr. Anthony faucet during a press conference on Friday. “But the information that you’re referring to specifically is anecdotal, it was not done in a controlled clinical trial. So, you really can’t make any definitive statement about it.”
A summary survey of various prospective treatments and their current status was published today in Medscape, and this includes the current state of redeliver and chloroquine investigations, as well as several other drugs being studied by researchers. As has been reported here and elsewhere, there are promising signs that they could prove effective in either treatment, or treatment and even preventative use (in the case of redeliver), but these are, as Dr. Fanucci puts it, only the first step that should lead to more sophisticated clinical studies, which themselves will then need competing peer studies to eventually prove out.
Longdom Publishing SL to accomplish its vision to make scientific information & health care open access has made a new initiation to enrich the scientific knowledge all around the world. As per the interest of the scientific community from Non-English-speaking territories, we have introduced a new feature in the name of language translation. Language translation helps the scientific community to go through the articles in Chinese, Japanese & other world languages.
A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System www.longdom.org/submissions/developing-drugs.html or as an email attachment to email@example.com
Journal of Developing Drugs